Literature DB >> 16040601

Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3.

Sarah J Shoesmith Berke1, Yaohui Chai, Ginger L Marrs, Hsiang Wen, Henry L Paulson.   

Abstract

Polyglutamine (polyQ) expansions cause neurodegeneration that is associated with protein misfolding and influenced by functional properties of the host protein. The polyQ disease protein, ataxin-3, has predicted ubiquitin-specific protease and ubiquitin-binding domains, which suggest that ataxin-3 functions in ubiquitin-dependent protein surveillance. Here we investigate direct links between the ubiquitin-proteasome pathway and ataxin-3. In neural cells we show that, through its ubiquitin interaction motifs (UIMs), normal or expanded ataxin-3 binds a broad range of ubiquitinated proteins that accumulate when the proteasome is inhibited. The expression of a catalytically inactive ataxin-3 (normal or expanded) causes ubiquitinated proteins to accumulate in cells, even in the absence of proteasome inhibitor. This accumulation of ubiquitinated proteins occurs primarily in the cell nucleus in transfected cells and requires intact UIMs in ataxin-3. We further show that both normal and expanded ataxin-3 can undergo oligoubiquitination. Although this post-translational modification occurs in a UIM-dependent manner, it becomes independent of UIMs when the catalytic cysteine residue of ataxin-3 is mutated, suggesting that ataxin-3 ubiquitination is itself regulated in trans by its own de-ubiquitinating activity. Finally, pulse-chase labeling reveals that ataxin-3 is degraded by the proteasome, with expanded ataxin-3 being as efficiently degraded as normal ataxin-3. Mutating the UIMs does not alter degradation, suggesting that UIM-mediated oligoubiquitination of ataxin-3 modulates ataxin-3 function rather than stability. The function of ataxin-3 as a de-ubiquitinating enzyme, its post-translational modification by ubiquitin, and its degradation via the proteasome link this polyQ protein to ubiquitin-dependent pathways already implicated in disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16040601     DOI: 10.1074/jbc.M506084200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

Review 2.  Strategies for the identification of novel inhibitors of deubiquitinating enzymes.

Authors:  Seth J Goldenberg; Jeffrey L McDermott; Tauseef R Butt; Michael R Mattern; Benjamin Nicholson
Journal:  Biochem Soc Trans       Date:  2008-10       Impact factor: 5.407

3.  Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities.

Authors:  Roland Hjerpe; Fabienne Aillet; Fernando Lopitz-Otsoa; Valerie Lang; Patrick England; Manuel S Rodriguez
Journal:  EMBO Rep       Date:  2009-10-02       Impact factor: 8.807

Review 4.  Machado-Joseph disease/spinocerebellar ataxia type 3.

Authors:  Henry Paulson
Journal:  Handb Clin Neurol       Date:  2012

Review 5.  Histone acetylation, acetyltransferases, and ataxia--alteration of histone acetylation and chromatin dynamics is implicated in the pathogenesis of polyglutamine-expansion disorders.

Authors:  Shaun D McCullough; Patrick A Grant
Journal:  Adv Protein Chem Struct Biol       Date:  2010       Impact factor: 3.507

6.  Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23.

Authors:  Jessica R Blount; Wei-Ling Tsou; Gorica Ristic; Aaron A Burr; Michelle Ouyang; Holland Galante; K Matthew Scaglione; Sokol V Todi
Journal:  Nat Commun       Date:  2014-08-21       Impact factor: 14.919

Review 7.  The ubiquitin proteasome system in neuropathology.

Authors:  Norman L Lehman
Journal:  Acta Neuropathol       Date:  2009-07-14       Impact factor: 17.088

8.  Axonal inclusions in spinocerebellar ataxia type 3.

Authors:  Kay Seidel; Wilfred F A den Dunnen; Christian Schultz; Henry Paulson; Stefanie Frank; Rob A de Vos; Ewout R Brunt; Thomas Deller; Harm H Kampinga; Udo Rüb
Journal:  Acta Neuropathol       Date:  2010-07-16       Impact factor: 17.088

9.  Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties.

Authors:  Ginny Marie Harris; Katerina Dodelzon; Lijie Gong; Pedro Gonzalez-Alegre; Henry L Paulson
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

10.  The UBA-UIM domains of the USP25 regulate the enzyme ubiquitination state and modulate substrate recognition.

Authors:  Amanda Denuc; Anna Bosch-Comas; Roser Gonzàlez-Duarte; Gemma Marfany
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.